•  
    2018


  • CFDA Granted Approval of Phase I to III Clinical Trials for XZP-3287,a Category 1.1 Innovative Drug
    2017

  • CFDA Granted Approval of Phase II/III Clinical Trials for Imigliptin Hydrochloride,a category 1.1 antidiabetic drug
    2016
  • The injectable antibiotic Benapenem, National Category 1.1 new drug, is tested on human for the first time. It is well tolerated in subjects;
    Covance and XuanZhu Pharma announce partnership for preclinical and clinical portfolio development;
    FPI is achieved in the US for Pirotinib, National Category 1.1 anti-cancer new drug;
    The IND of national Category 1.1 anti-oncology new drug Sirotinib is approved by CFDA;
    CFDA granted IND applications to Pirotinib Hydrochloride, a category 1.1 anti-oncology drug. 
    2015
  • The national Category 1.1 anti-hypertensive new drug Tylerdipine Hydrochloride is approved by CFDA for clinical trials as Category One new drug;
    The IND filling of national Category 1.1 anti-oncology innovative patent drug Pirotinib Hydrochloride is approved by FDA for clinical studies.
    2014




  • The national Category 1.1 anti-diabetic drug Imigliptin Hydrochloride is approved by CFDA for clinical trials as Category One new drug;
    The national Category 1.1 anti-acid drug Anaprazole Sodium is approved by CFDA for clinical trials as Category One new drug;
    Both the preclinical study of Imigliptin Hydrochloride and clinical study of Benapenem for injection are awared the National Priority 12-5 Projects.
    2013

  • A wholly owned subsidiary of Sihuan Pharmaceutical Holdings Group Ltd.;
    The national Category 1.1 antibiotic new drug Benapenem is approved by CFDA for clinical trials as Category One new drug.
    2012





  • The national Category 1.1 antibiotic new drug Apapenem is approved by CFDA for clinical trials as Category One new drug;
    The national Category 1.1 antibiotic new drug Benapenem was awarded the National Priority 12-5 Project.
    2011

  • The national Category 1.1 antibiotic new drug Apapenem was awarded National Priority 11-5 Project;
    4 IND applications filed to CFDA in 2010.
    2010


  • First IND filed to CFDA, multiple CRCDs identified and a good product line established.
    2009


  • Officially became New Drug Research Institute of Sihuan Pharmaceutical Holdings Group Ltd.
    2008


  • Founded in Jinan, dedicated to research and development of innovative drugs.
    2002
    -
    2007

Email | Terms of Use | Contact us

2014版權?軒竹醫藥科技有限公司保留所有權利 魯ICP備09030169號

青海快3十大规律 二组平特三连肖论坛 神来棋牌旧版下载 三分彩开奖软件下载 股票趋势交易软件 中国教育资源分配现 常来海南麻将大鬼黑a 微信捕鱼漏洞免费到账2000 韩国28开奖结果 友乐广西麻将安卓官网 平特一肖怎么玩最稳